| a. This is a case of incomplete dominance. | ||
| b. This is a case of dominant inheritance. | ||
| c. This is a case of recessive inheritance. | ||
| d. This is a case of Mendelian inheritance. |
| a. The husband is right; he cannot be the father. The father of the child must have AB or B blood type. | ||
| b. The husband is right; he cannot be the father. The father of the child must have O blood type. | ||
| c. The husband is wrong. He can be the father, if his genotype is AO. | ||
| d. The husband is wrong. He can be the father, if his genotype is AA. |
| a. 1 in 16 | ||
| b. 2 in 16 | ||
| c. 3 in 16 | ||
| d. 9 in 16 |
| a. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be blue-eyed and have Bb or BB genotype. | ||
| b. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be blue-eyed and have Bb or BB genotype. | ||
| c. No, because Jane has BB genotype and Joe has Bb genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be brown-eyed and have Bb or BB genotype. | ||
| d. No, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be brown-eyed and have Bb or BB genotype. |
| a. Conventional PCR | ||
| b. RT-PCR | ||
| c. Real-time RT-PCR | ||
| d. Subtractive hybridization |
| a. 4 | ||
| b. 8 | ||
| c. 16 | ||
| d. 32 |
| a. Ribozymes | ||
| b. RNAi | ||
| c. MicroRNA | ||
| d. Riboswithes |
| a. In the cgfp gene, the codon usage is C. reinhardtii-conform. | ||
| b. The cgfp gene is expressing a different GFP protein sequence. | ||
| c. The cgfp gene is expressing a GFP protein with different color. | ||
| d. In the cgfp gene, there are fewer introns. |
| a. Conventional PCR | ||
| b. RT-PCR | ||
| c. Real-time RT-PCR | ||
| d. Subtractive hybridization. |
| a. Radioactive | ||
| b. Fluorescent | ||
| c. Silver-enhanced gold | ||
| d. Photoenhanced |
| a. Junk DNA | ||
| b. Pseudogene | ||
| c. Long repeat | ||
| d. Non-coding region |
| a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. | ||
| b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. | ||
| c. Scaffolds are sequenced and contigs are built from scaffolds. | ||
| d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
| a. Divergence, common ancestor | ||
| b. Distance, common ancestor | ||
| c. Divergence, distance | ||
| d. Distance, adaptation |
| a. Higher | ||
| b. Lower | ||
| c. Unchanged | ||
| d. Negligible |
| a. Genes which are not expressed differentially in tumor and normal cells. | ||
| b. Genes which are overexpressed in normal cells. | ||
| c. Genes which are overexpressed in tumor cells. | ||
| d. Promoter sequences which are particularly active in tumor cells. |
| a. RNA-protein interaction prediction. | ||
| b. Gene prediction. | ||
| c. Open reading frame prediction. | ||
| d. Nucleic acid sequence translation to protein sequence. |
| a. Euchromatin | ||
| b. Heterochromatin | ||
| c. Telomere | ||
| d. Centromere |
| a. Short known DNA sequences can be synthesized chemically directly on chip. | ||
| b. All genes of an organism can be bound in microarrays, and these arrays can be used in differential gene expression studies. | ||
| c. Microarrays made from the genome of an organism are typically probed with a whole genomic DNA probe made from the same organism. | ||
| d. Fluorescent probes can be used to identify genes on microarrays. |
| a. 10 and 6 | ||
| b. 11 and 6 | ||
| c. 14 and 6 | ||
| d. 11 and 10 |
| a. DNA extraction, restriction enzymes, and Southern blot | ||
| b. DNA extraction, PCR, and Southern blot | ||
| c. DNA extraction, restriction enzymes, and Western blot | ||
| d. DNA extraction, PCR, and Western blot |
| a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. | ||
| b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. | ||
| c. Scaffolds are sequenced and contigs are built from scaffolds. | ||
| d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
| a. A single nucleotide change. | ||
| b. A single codon change. | ||
| c. A single amino acid change. | ||
| d. A small genetic change. |
| a. The ratio of poly-Q and poly-A | ||
| b. The total length of poly-Q and poly-A | ||
| c. Only the length of poly-Q | ||
| d. Only the length of poly-A |
| a. Proteomics | ||
| b. Metagenomics | ||
| c. Metabolomics | ||
| d. Proteomics |
| a. ABC | ||
| b. ACB | ||
| c. CAB | ||
| d. CBA |
| a. Metagenomics | ||
| b. Envirogenomics | ||
| c. Nature genomics | ||
| d. Microbiomics |
| a. Genetic map. | ||
| b. Physical map | ||
| c. Open reading frame | ||
| d. Gene sequence |
| a. Model organisms have genes similar to human genes. | ||
| b. Model organisms are mainly used to highlight the differences between animals and humans. | ||
| c. Model organisms can attract animal-loving students to genomics. | ||
| d. A focus on the differences contributes to our understanding of genetic inheritance. |
| a. Proteomics | ||
| b. Metagenomics | ||
| c. Metabolomics | ||
| d. Proteomics |
| a. Crossing over of the sister chromatids during meiosis I. | ||
| b. Crossing over of the non-sister chromatids during meiosis I. | ||
| c. Crossing over of the sister chromatids during meiosis II. | ||
| d. Crossing over of the non-sister chromatids during meiosis II. |
| a. Design gene therapy | ||
| b. Clone animals | ||
| c. Combine functional units of different proteins | ||
| d. Generate novel cell types |
| a. Cell differentiation | ||
| b. Meiosis | ||
| c. The locus of gene insertion | ||
| d. Codon preference |
| a. Transposable elements | ||
| b. Proteases | ||
| c. Epigenetic changes | ||
| d. DNA methylation |
| a. Lysosomes | ||
| b. Extracellular space | ||
| c. Nucleus | ||
| d. Golgi |
| a. Affinity chromatography and immunoprecipitation | ||
| b. Exclusion chromatography and immunoprecipitation | ||
| c. Western blot and exclusion chromatography | ||
| d. Western blot and Northern blot |
| a. Higher temperatures utilizing the increased Brownian motion | ||
| b. The presence of complementing surfaces | ||
| c. Processing enzymes which seal the protein in the right conformation with chemical bonds | ||
| d. Chaperones that prevent premature aggregation of hydrophobic regions |
| a. Dideoxy sequencing | ||
| b. Edman degradation | ||
| c. MALDI | ||
| d. MS-MS |
| a. Dideoxy sequencing | ||
| b. Edman degradation | ||
| c. MALDI | ||
| d. MS-MS |
| a. Can be modified posttranslationally | ||
| b. Cannot be modified posttranslationally | ||
| c. Are spontaneously secreted | ||
| d. Are synthesized on ribosomes |
| a. A separate surface from the DNA | ||
| b. The surface as the DNA | ||
| c. An antibody capture array | ||
| d. A functional array |
| a. Greatly | ||
| b. Hardly | ||
| c. Never | ||
| d. Temporarily |
| a. Simultaneously, enhancers | ||
| b. Simultaneously, operons | ||
| c. Consecutively, enhancers | ||
| d. Consecutively, operons |
| a. Eastern blot | ||
| b. Northern blot | ||
| c. Southern blot | ||
| d. Western blot |
| a. Size | ||
| b. Shape | ||
| c. Electric charge | ||
| d. Polarity |
| a. Burst | ||
| b. Stay intact | ||
| c. Shrink | ||
| d. Divide |
| a. Genomes | ||
| b. Viruses | ||
| c. Plasmids | ||
| d. Vectors |
| a. Reporter genes | ||
| b. Selection genes | ||
| c. Detection genes | ||
| d. Promoters |
| a. Knock-out | ||
| b. Random insertion | ||
| c. Mutated | ||
| d. Inverted |
| a. Providing extracellular matrix for | ||
| b. Adding Ti plasmid to the growth medium of | ||
| c. Inducing de-differentiation of | ||
| d. Inducing viral gene transfer of |
| a. Zinc | ||
| b. Iron | ||
| c. Selenium | ||
| d. flavin |
| a. Somatic | ||
| b. Multipotent stem | ||
| c. Totipotent stem | ||
| d. Germ |
| a. Only recessive homozygous | ||
| b. Only homozygous traits | ||
| c. Only dominant genes | ||
| d. A desired combination of recessive and dominant genes |
| a. Hair shaft | ||
| b. Saliva | ||
| c. Blood | ||
| d. Milk |
| a. Genetic mosaics | ||
| b. Hybridomas | ||
| c. Genetic mixtures | ||
| d. Hybrids |
| a. Somatic cell nuclear transfer | ||
| b. Germ line nuclear transfer | ||
| c. In vitro fertilization | ||
| d. Recombineering |
| a. Her shorter than average | ||
| b. Her longer than average | ||
| c. The absence of the | ||
| d. The branching |
| a. Forward genetic | ||
| b. Reverse genetic | ||
| c. Transgenic | ||
| d. Mutagenic |
| a. Substantial homologous | ||
| b. Minimal homologous | ||
| c. Substantial heterologous | ||
| d. Minimal heterologous |
| a. Site specific insertion; neutralization of position effects | ||
| b. Neutralization of position effects; site specific insertion | ||
| c. P element insertion; recombinases and integrases | ||
| d. Recombinases and integrases; P element insertion. |
| a. offer protection against | ||
| b. enhance | ||
| c. attenuate insect bites delivering | ||
| d. intensify |
| a. Preimplantation genetic diagnosis | ||
| b. Postimplantation genetic diagnosis | ||
| c. Prefertilization genetic diagnosis | ||
| d. Genetic counseling |
| a. Blue fluorescent protein | ||
| b. Green fluorescent protein | ||
| c. Red fluorescent protein | ||
| d. Yellow fluorescent protein |
| a. Insertion position | ||
| b. Activity | ||
| c. High copy number | ||
| d. Inactivity |
| a. DNA methylation | ||
| b. Chromosomal rearrangement | ||
| c. Missense mutation | ||
| d. Chromosomal inversion |
| a. 16 % | ||
| b. 30% | ||
| c. 40% | ||
| d. 90% |
| a. Stem cells; virus transformed cells | ||
| b. Blood cells; virus transformed cells | ||
| c. Stem cells; mutated cells | ||
| d. Blood cells; mutated cells |
| a. Zinc-finger nuclease | ||
| b. Protease | ||
| c. Antibody | ||
| d. Lipase |
| a. Every; every | ||
| b. Every; a tumor | ||
| c. A tumor, a tumor | ||
| d. A tumor, every |
| a. 0% | ||
| b. 25% | ||
| c. 50% | ||
| d. 75% |
| a. Point; malaria parasite | ||
| b. Nonsense; malaria parasite | ||
| c. Point; papillomavirus | ||
| d. Nonsense; papillomavirus |
| a. Gene gun, gold | ||
| b. Gene gun, iron | ||
| c. Particle gun, gold | ||
| d. Particle gun, iron |
| a. Turner | ||
| b. Klinefelter | ||
| c. Down | ||
| d. Edwards |
| a. Not wear off as we age; can | ||
| b. Wear off as we age; can | ||
| c. Not wear off as we age; cannot | ||
| d. Wear off as we age; cannot |
| a. Noncoding chromosomal regions | ||
| b. Coding chromosomal regions | ||
| c. One chromosome | ||
| d. Sex chromosomes |
| a. Simplicity of | ||
| b. Instantaneous result of | ||
| c. Statistical strength linked to | ||
| d. Variety of available protocols for |
| a. If a Y-typing is performed and shows that Mr. X's Y chromosome is identical to the Y chromosome of Ms. Y's son, then Mr. X must be the father. | ||
| b. If a Y-typing is performed and shows that Mr. X's Y chromosome is identical to the Y chromosome of Ms. Y's son, then Mr. X or another man of his paternal line must be the father. | ||
| c. If forensic DNA-typing is performed utilizing the standard 13 STR regions and shows that Mr. Y's son has one-one allele of Mr. X's each analyzed STR allele pair, then Mr. X must be the father. | ||
| d. DNA fingerprinting cannot prove that Mr. X is the father of Ms. Y's son. But if they are father and son, their friction ridge patterns will be identical on all of their fingers. |
| a. Fermentation | ||
| b. Extraction | ||
| c. Bioaccumulation | ||
| d. Bioamplification |
| a. Single-species; multi-species | ||
| b. Multi-species; single-species | ||
| c. Single-layer; multi-layer | ||
| d. Multi-layer; single-layer |
| a. Biochemical reactions | ||
| b. Microbes | ||
| c. Plants | ||
| d. Animals |
| a. As carbonate-based concrete | ||
| b. As Roman-style | ||
| c. As concrete | ||
| d. Underground |
| a. Fermentation | ||
| b. Extraction | ||
| c. Bioaccumulation | ||
| d. Bioamplification |
| a. Simple; longer | ||
| b. Technologically challenging; shorter | ||
| c. Simple; shorter | ||
| d. Technologically challenging; longer |
| a. Bacteria | ||
| b. Plants | ||
| c. Birds | ||
| d. Fishes |
| a. Simple; longer | ||
| b. Technologically challenging; shorter | ||
| c. Simple; shorter | ||
| d. Technologically challenging; longer |
| a. Soluble in fat. | ||
| b. Hydrophilic. | ||
| c. Stable. | ||
| d. Biologically active. |
| a. Bacteria | ||
| b. Plant | ||
| c. Bird | ||
| d. Fish |
| a. Four | ||
| b. Five | ||
| c. Six | ||
| d. Seven |
| a. Chemostat | ||
| b. Traditional liquid culture | ||
| c. Semisolid culture | ||
| d. Subculture |
| a. Bioleaching | ||
| b. Bioremediation | ||
| c. In situ | ||
| d. Biofilm |
| a. Hydrogenases | ||
| b. Hydrogen ion pumps | ||
| c. Electron transport chain | ||
| d. ATP |
| a. isobutanol | ||
| b. glucose | ||
| c. penicillin | ||
| d. hydrogen |
| a. Just a fancy name for a multivitamin complex | ||
| b. An antigen engineered into a plant we eat | ||
| c. An attenuated oral vaccine, like the Sabin drops | ||
| d. An antibody engineered into the plant we eat |
| a. Saccharopolyspora erythraea | ||
| b. Saccharomyces cerevisiae | ||
| c. Streptomyces parvullus | ||
| d. Clostridium cellulolyticum |
| a. Lead to gene doping | ||
| b. Initiate intensive wellness activities | ||
| c. Can be easily accepted in sports | ||
| d. Might to be legalized soon |
| a. Genetic counseling | ||
| b. Pharmacogenomics | ||
| c. Pharmacokinetics | ||
| d. Pharmacology |
| a. Protect against the body's immune response | ||
| b. Bring another alternative to the market | ||
| c. Follow these particles with body scanning | ||
| d. Determine how fat particles leaves the body |
| a. to build organs that are not rejected | ||
| b. for future applications | ||
| c. for donation | ||
| d. in cloning |
| a. Embryonic stem cells | ||
| b. Somatic stem cells | ||
| c. Adult stem cells | ||
| d. Multipotent stem cells |
| a. Mycoplasma Laboratorium | ||
| b. Agrobacterium tumefaciens | ||
| c. Escherichia coli | ||
| d. Saccharomyces cerevisiae |
| a. Radioimmunotherapy | ||
| b. Radiotoxins | ||
| c. Radiation therapy | ||
| d. Chemotherapy |